Oppenheimer Asset Management Inc. Biogen Inc. Transaction History

Oppenheimer Asset Management Inc.

$8.04 Billion
Q3 2024

A detailed history of Oppenheimer Asset Management Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Oppenheimer Asset Management Inc. holds 35,928 shares of BIIB stock, worth $5.26 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

35,928

Previous 36,767 2.28%

Holding current value

$5.26 Million

Previous $8.52 Million 18.29%

% of portfolio

0.09%

Previous 0.11%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	SELL	$189.07 - $236.8 $158,629 - $198,675	-839 Reduced 2.28%	35,928 $6.96 Million
Q2 2024 Aug 08, 2024	BUY	$190.52 - $236.72 $530,979 - $659,738	2,787 Added 8.2%	36,767 $8.52 Million
Q1 2024 May 06, 2024	SELL	$212.02 - $267.71 $979,320 - $1.24 Million	-4,619 Reduced 11.97%	33,980 $7.33 Million
Q4 2023 Feb 13, 2024	SELL	$222.59 - $267.94 $622,361 - $749,160	-2,796 Reduced 6.75%	38,599 $9.99 Million
Q3 2023 Nov 07, 2023	BUY	$253.3 - $285.89 $31,155 - $35,164	123 Added 0.3%	41,395 $10.6 Million
Q2 2023 Aug 02, 2023	SELL	$275.25 - $318.06 $112,852 - $130,404	-410 Reduced 0.98%	41,272 $11.8 Million
Q1 2023 May 10, 2023	SELL	$256.56 - $292.34 $126,740 - $144,415	-494 Reduced 1.17%	41,682 $11.6 Million
Q4 2022 Feb 06, 2023	SELL	$252.44 - $306.72 $1.27 Million - $1.54 Million	-5,023 Reduced 10.64%	42,176 $11.7 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $273,928 - $377,723	1,407 Added 3.07%	47,199 $12.6 Million
Q2 2022 Aug 08, 2022	SELL	$187.54 - $223.02 $11,439 - $13,604	-61 Reduced 0.13%	45,792 $9.34 Million
Q1 2022 May 12, 2022	BUY	$193.77 - $244.14 $53,286 - $67,138	275 Added 0.6%	45,853 $9.66 Million
Q4 2021 Feb 02, 2022	SELL	$223.92 - $287.77 $1.56 Million - $2 Million	-6,960 Reduced 13.25%	45,578 $10.9 Million
Q3 2021 Nov 12, 2021	BUY	$282.99 - $369.05 $728,699 - $950,303	2,575 Added 5.15%	52,538 $14.9 Million
Q2 2021 Aug 03, 2021	BUY	$259.0 - $414.71 $939,134 - $1.5 Million	3,626 Added 7.83%	49,963 $17.3 Million
Q1 2021 May 17, 2021	BUY	$242.95 - $284.63 $626,082 - $733,491	2,577 Added 5.89%	46,337 $13 Million
Q4 2020 Feb 11, 2021	BUY	$236.26 - $355.63 $798,558 - $1.2 Million	3,380 Added 8.37%	43,760 $10.7 Million
Q3 2020 Nov 13, 2020	BUY	$264.77 - $305.71 $533,511 - $616,005	2,015 Added 5.25%	40,380 $11.5 Million
Q2 2020 Aug 11, 2020	BUY	$258.66 - $342.55 $1.27 Million - $1.68 Million	4,907 Added 14.67%	38,365 $10.3 Million
Q1 2020 May 08, 2020	BUY	$268.85 - $341.04 $705,193 - $894,547	2,623 Added 8.51%	33,458 $10.6 Million
Q4 2019 Feb 07, 2020	BUY	$220.06 - $304.07 $62,717 - $86,659	285 Added 0.93%	30,835 $9.15 Million
Q3 2019 Oct 31, 2019	BUY	$217.44 - $243.88 $585,565 - $656,768	2,693 Added 9.67%	30,550 $7.11 Million
Q2 2019 Aug 09, 2019	BUY	$219.29 - $241.72 $1.21 Million - $1.34 Million	5,526 Added 24.75%	27,857 $6.52 Million
Q1 2019 Apr 24, 2019	BUY	$216.71 - $338.96 $635,393 - $993,830	2,932 Added 15.11%	22,331 $5.28 Million
Q4 2018 Jan 30, 2019	BUY	$278.5 - $352.75 $193,557 - $245,161	695 Added 3.72%	19,399 $5.84 Million
Q3 2018 Oct 26, 2018	SELL	$293.51 - $383.83 $387,726 - $507,039	-1,321 Reduced 6.6%	18,704 $6.61 Million
Q2 2018 Aug 10, 2018	BUY	$257.52 - $306.91 $694,531 - $827,736	2,697 Added 15.56%	20,025 $5.81 Million
Q1 2018 May 09, 2018	BUY	$260.13 - $367.91 $645,902 - $913,520	2,483 Added 16.73%	17,328 $4.75 Million
Q3 2017 Nov 14, 2017	BUY	$281.15 - $329.69 $4.17 Million - $4.89 Million	14,845	14,845 $4.65 Million

Others Institutions Holding BIIB

# of Institutions

1,037

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.

Account

Oppenheimer Asset Management Inc. Biogen Inc. Transaction History